Sequential Compression Biomechanical Device Versus Primary Amputation in Patients With Critical Limb Ischemia

Tawfick, Wael; Hamada, Nader; Soylu, Esraa; Fahy, Anne; Hynes, Niamh; Sultan, Sherif

doi:10.1177/1538574413499413

Cited by 20 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, oedema and excess non-physiological growth of capillaries in the retina have been detected as adverse effects of the VEGF gene therapy and again issues arise related to transduction efficiency, route of administration, vector type, dose, and duration of treatment to achieve optimal therapeutic angiogenesis. 49 Research on therapeutic angiogenesis is ongoing, whether mechanically by sequential pneumatic compression, 50,51 or with the use of cell-based therapy, such as gene delivery of pro-angiogenic growth factors. 52–54…”

Section: Angiogenesis In Ischaemic Musclementioning

confidence: 99%

Stem Cell Smart Technology, where are we now and how far we have to go?

et al. 2017

Self Cite

View full text Add to dashboard Cite

Approximately eight million people in the United States have peripheral arterial disease, which increases exponentially with age. There have been a plethora of available treatments including surgery, angioplasty, atherectomy, laser technology, and cell-based therapies. Cell-based therapies were developed in the hope of translating laboratory-based technology into clinical successes. However, clinical results have been disappointing. Infusion or injection for stem cell therapy is still considered experimental and investigational, and major questions on safety and durability have arisen. In no option patients, how can they be treated safely and successfully? In this article, we review contemporary practice for cell therapy, its pitfalls and breakthroughs, and look at the future ahead. We introduce a novel smart system for minimally invasive delivery of cell therapies, which exemplifies the next generation of endovascular solutions to stem cell technology and promises safety, efficacy, and reliability.

show abstract

Section: Angiogenesis In Ischaemic Musclementioning

confidence: 99%

Stem Cell Smart Technology, where are we now and how far we have to go?

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Intermittent pneumatic compression pumps have been modified in recent years to provide treatment for different medical conditions such as critical limb ischaemia (Tawfick et al, 2013) and chronic wounds (O'Sullivan-Drombolis and Houghton, 2009). All applications are concerned with the reduction of oedema in some way, based on hypothetical possible physiological effects during treatment (Morris, 2008).…”

Section: Development Of the Lymphflow Advancementioning

confidence: 99%

Lymphoedema management with the LymphFlow Advance pneumatic compression pump

Lee

Wigg²,

Pugh³

et al. 2016

Br J Community Nurs

View full text Add to dashboard Cite

There are many intermittent pneumatic compression devices available for use in the management and adjunct treatment of lymphatic, venous and arterial disease. This article discusses the development of a new advanced pneumatic compression device, the LymphFlow Advance, which can perform focussed treatment on the lymphoedematous area using a variety of different cycles. Case studies with therapist and patient feedback are used to demonstrate the use of the LymphFlow Advance in the lymphoedema clinic, with a discussion of the evidence to underpin recommended treatment regimes.

show abstract

“…However, at the end of 90 days, the CLI patients did not require any intervention, the ischaemic ulcer healed and there was no need for any pain medications. [14][15][16][17][18] Skeletal muscle pathophysiology in CLI Peripheral arterial disease is not clinically manifested in a uniform manner. More than 90% of patients with PAD never actually progress to CLI.…”

Section: Introductionmentioning

confidence: 99%

Minimising failure in critical lower limb ischaemia intervention: Adjuvant capillary bed recruitment is the missed opportunity

2018

Self Cite

View full text Add to dashboard Cite

Critical limb ischaemia is the end stage of peripheral arterial disease before limb loss. Contemporary interventions to restore blood flow have high morbidity and mortality and fail to provide sustained restoration of peripheral circulation. Cell-based therapies designed to promote neovascularisation or angiogenesis have been shown in trials to be safe but clinically ineffective. Notwithstanding endless research in the area, no headway has been made in identifying a successful therapy designed specifically to target muscle disease in critical lower limb ischaemia. Thus, the quest to find an effective, lasting solution for critical lower limb ischaemia continues and requires more innovative therapeutic tactics. Our aim is to highlight the crucially interlinked role of the capillary bed, skeletal muscle mass and mitochondria in critical lower limb ischaemia patients and to identify novel therapeutic mechanisms that the vascular interventionalist can add to their armamentarium.

show abstract

Sequential Compression Biomechanical Device Versus Primary Amputation in Patients With Critical Limb Ischemia

Abstract: The SCBD therapy is a cost-effective and clinically effective solution in patients with CLI having no option of revascularization. It provides adequate limb salvage while providing relief of rest pain without any intervention.

Cited by 20 publications

References 29 publications

Stem Cell Smart Technology, where are we now and how far we have to go?

Stem Cell Smart Technology, where are we now and how far we have to go?

Lymphoedema management with the LymphFlow Advance pneumatic compression pump

Minimising failure in critical lower limb ischaemia intervention: Adjuvant capillary bed recruitment is the missed opportunity

Contact Info

Product

Resources

About